To use this site, please disable the ad blocking feature and reload the page.
This website uses cookies to collect information about your visit for purposes such as showing you personalized ads and content, and analyzing our website traffic. By clicking “Accept all,” you will allow the use of these cookies.
Users accessing this site from EEA countries and UK are unable to view this site without your consent. We apologize for any inconvenience caused.
The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan’s Eisai and partner Biogen’s Alzheimer’s drug Leqembi, the companies said on Monday.
